Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases

References

• Bousquet J, Bachert C, Canonica GW, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124(3):428–433. .
   PubMed Web of Science ®Google Scholar
• Achakulwisut P, Brauer M, Hystad P, et al. Global, national, and urban burdens of paediatric asthma incidence attributable to ambient NO2 pollution: estimates from global datasets. Lancet Planet Health. 2019;3(4):e166–e178.
   PubMedGoogle Scholar
• Passali D, Cingi C, Staffa P, et al. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):e7–e7.
   PubMed Web of Science ®Google Scholar
• Collaborators GCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691–706.
   PubMed Web of Science ®Google Scholar
• Jin J-M, Sun Y-C. Allergy and chronic obstructive pulmonary disease. Chin Med J (Engl). 2017;130(17):2017–2020.
   PubMed Web of Science ®Google Scholar
• Jamieson DB, Matsui EC, Belli a, et al., Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188(2): 187–192.
   PubMed Web of Science ®Google Scholar
• Global Health Estimates. Deaths by cause, age, sex, by country and by region. Geneva: World Health Organization; 2016. p. 2000–2016.
   Google Scholar
• Hens G, Vanaudenaerde BM, Bullens DMA, et al. Original article: sinonasal pathology in nonallergic asthma and COPD: ‘united airway disease’ beyond the scope of allergy: sinonasal pathology in nonallergic asthma and COPD. Allergy. 2007;63(3):261–267.
   PubMed Web of Science ®Google Scholar
• Yii ACA, Tay TR, Choo XN, et al. Precision medicine in united airways disease: a “treatable traits” approach. Allergy. 2018;73(10):1964–1978.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. LID - 1900164 [pii] LID – DOI:10.1183/13993003.00164-2019.
   Google Scholar
• Global Initiative for asthma. Global strategy for asthma management and prevention, 2018. [ cited 2020 Mar 1]]. Available from: www.ginasthma.org
   Google Scholar
• Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2017;119(6):489–511.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Liu H, Pham T-H, et al. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;20(1):14.
   PubMedGoogle Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol. 2019;7(7):2447–2449.
   Web of Science ®Google Scholar
• Masieri S, Cavaliere C, Begvarfaj E, et al. Effects of omalizumab therapy on allergic rhinitis: a pilot study. (2284-0729 (Electronic)).
   Google Scholar
• European Academy of Allergy and Clinical Immunology, Global Atlas of Aallergy. June 2019.
   Google Scholar
• Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13(5):e1002024.
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang Y, Chen H, et al., Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection 2019; 47(3): 377–385.
   Google Scholar
• Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clinl Infect Dis. 2019;68(9):1482–1493..
   PubMed Web of Science ®Google Scholar
• Seemungal TAR, Harper-Owen R, Bhowmik a, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 2000;16(4):677. .
   PubMed Web of Science ®Google Scholar
• Bjerregaard a, Laing IA, Poulsen N, et al. Characteristics associated with clinical severity and inflammatory phenotype of naturally occurring virus-induced exacerbations of asthma in adults. Respir Med. 2017;123:34–41..
   PubMed Web of Science ®Google Scholar
• Stefan MS, Shieh M-S, Spitzer KA, et al. Association of antibiotic treatment with outcomes in patients hospitalized for an asthma exacerbation treated with systemic corticosteroids. JAMA Intern Med. 2019;179(3):333–339.
   PubMed Web of Science ®Google Scholar
• Abt MC, Osborne LC, Monticelli LA, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012;37(1):158–170.
   PubMed Web of Science ®Google Scholar
• Li N, Ma W-T, Pang M, et al. The commensal microbiota and viral infection: a comprehensive review. Front Immunol. 2019;10:1551.
   PubMed Web of Science ®Google Scholar
• Lee KH, Gordon a, Shedden K, et al. The respiratory microbiome and susceptibility to influenza virus infection. Plos One. 2019;14(1):e0207898. en. .
   Web of Science ®Google Scholar
• Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259–1260. en.
   PubMed Web of Science ®Google Scholar
• Haahtela, T. A biodiversity hypothesis. Allergy. 2019;74(8):1445–1456.
   Google Scholar
• Rook GAW. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(1):5–15..
   PubMed Web of Science ®Google Scholar
• Marsland BJ, Trompette A, Gollwitzer ES The gut-lung axis in respiratory disease. (2325-6621 (Electronic)).
   Google Scholar
• Anand S, Mande SS. Diet, microbiota and gut-lung connection. Front Microbiol. 2018;9:2147.
   PubMed Web of Science ®Google Scholar
• Dang AT, Marsland BJ. Microbes, metabolites, and the gut–lung axis. Mucosal Immunol. 2019 Jul 01;12(4):843–850.
   PubMed Web of Science ®Google Scholar
• Esposito S, Soto-Martinez ME, Feleszko W, et al., Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 18(3): 198–209. en. 2018.
   PubMed Web of Science ®Google Scholar
• Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012 Jan 01;5(1):7–18.
   PubMed Web of Science ®Google Scholar
• Navarro S, Cossalter G, Chiavaroli C, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011;4(1):53–65.
   PubMed Web of Science ®Google Scholar
• Feleszko W, Jaworska J, Hamelmann E. Toll-like receptors—novel targets in allergic airway disease (probiotics, friends and relatives). Eur J Pharmacol. 2006;533(1–3):308–318.
   PubMed Web of Science ®Google Scholar
• Debock I, Flamand V. Unbalanced neonatal CD4(+) T-cell immunity. Front Immunol. 2014;5:393.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Artis D. New paradigms in type 2 immunity. Science. 2012;3376093:431–435.
   PubMed Web of Science ®Google Scholar
• Spisek R, Brazova J, Rozkova D, et al. Maturation of dendritic cells by bacterial immunomodulators. Vaccine. 2004 Jul 29;22(21–22):2761–2768. PubMed PMID: WOS:000223001900015.
   PubMed Web of Science ®Google Scholar
• Hu X, Zheng W, Wang L, et al. The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide pidotimod(PTD). Hum Vaccin Immunother. 2012 Sep;8(9):1250–1258.
   PubMed Web of Science ®Google Scholar
• Bystron J, Hermanova Z, Szotkovska J, et al. Comparison of the effect of ribosomal immunotherapy on plasma levels of total IgE and cytokines IL-4, IL-5, IL-12 and IFN gamma in adult atopic and non-atopic patients during the pollen season. Clin Drug Investig. 2004;24(12):755–760.
   PubMed Web of Science ®Google Scholar
• Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677–689.
   PubMed Web of Science ®Google Scholar
• Kearney SC, Dziekiewicz M, Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol. 2015 May;114(5):364–369.
   PubMed Web of Science ®Google Scholar
• Mortaz E, Adcock IM, Folkerts G, et al. Probiotics in the Management of Lung Diseases. Mediators Inflamm. 2013;2013:1–10.
   Web of Science ®Google Scholar
• Papizadeh M, Rohani M, Nahrevanian H, et al. Probiotic characters of Bifidobacterium and Lactobacillus are a result of the ongoing gene acquisition and genome minimization evolutionary trends. Microb Pathog. 2017;111:118–131.
   PubMed Web of Science ®Google Scholar
• Obieglo K, van Wijck Y, de Kleijn S, et al. Microorganism-induced suppression of allergic airway disease: novel therapies on the horizon? Expert Rev Respir Med. 2014;8(6):717–730.
   PubMed Web of Science ®Google Scholar
• Feleszko W, Jaworska J, Rha RD, et al., Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy. 2007; 37(4): 498–505.
   Google Scholar
• Anatriello E, Cunha M, Nogueira J, et al. Oral feeding of Lactobacillus bulgaricus N45.10 inhibits the lung inflammation and airway remodeling in murine allergic asthma: relevance to the Th1/Th2 cytokines and STAT6/T-bet. Cell Immunol. 2019;341:103928.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang Y, He C, et al. Probiotics supplementation in children with asthma: a systematic review and meta-analysis: probiotics in children with asthma. J Paediatr Child Health. 2018;54(9):953–961.
   PubMed Web of Science ®Google Scholar
• Wei, X., Jiang, P., Liu, J, et al. Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials. Journal of Asthma 2020; 57(2), 167–178.
   Google Scholar
• Zuccotti G, Meneghin F, Aceti a, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy. 2015;70(11):1356–1371. .
   PubMed Web of Science ®Google Scholar
• Edwards MR, Walton RP, Jackson DJ, et al. The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. Allergy. 2018;73(1):50–63.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Takeshita T, Nanno M, et al. Modulation of natural killer cell activity by supplementation of fermented milk containing Lactobacillus casei in habitual smokers. Prev Med. 2005;40(5):589–594.
   PubMed Web of Science ®Google Scholar
• Mortaz E, Adcock IM, Ricciardolo FLM, et al. Anti-inflammatory effects of lactobacillus rahmnosus and bifidobacterium breve on cigarette smoke activated human macrophages. Plos One. 2015;10(8):e0136455. .
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: european position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinol J. 2012;50(1):1–12.
   PubMed Web of Science ®Google Scholar
• Reh DD, Higgins TS, Smith TL. Impact of tobacco smoke on chronic rhinosinusitis: a review of the literature. Int Forum Allergy Rhinol. 2012;2(5):362–369 en.
   PubMed Web of Science ®Google Scholar
• Krysko O, Holtappels G, Zhang N, et al. Alternatively activated macrophages and impaired phagocytosis of S. aureus in chronic rhinosinusitis: phagocytosis and macrophage phenotype in CRS. Allergy. 2011;66(3):396–403.
   PubMed Web of Science ®Google Scholar
• Foreman a, Holtappels G, Psaltis AJ, et al. Adaptive immune responses in Staphylococcus aureus biofilm-associated chronic rhinosinusitis: immune responses in S. aureus biofilm-associated CRS. Allergy. 2011;66(11):1449–1456.
   PubMed Web of Science ®Google Scholar
• Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. 2012;130(5):1087–1096.
   PubMed Web of Science ®Google Scholar
• Van, Zele T, Gevaert P, et al. Local immunoglobulin production in nasal polyposis is modulated by superantigens. Clin Exp Allergy. 2007;37(12):1840–1847..
   PubMed Web of Science ®Google Scholar
• Cervin AU. The potential for topical probiotic treatment of chronic rhinosinusitis, a personal perspective. Front Cell Infect Microbiol. 2018;7:530.
   PubMed Web of Science ®Google Scholar
• Stubbendieck RM, Straight PD. Multifaceted Interfaces of Bacterial Competition. J Bacteriol. 2016;198(16):2145–2155.
   PubMed Web of Science ®Google Scholar
• Yang Y, Jing Y, Yang J, et al. Effects of intranasal administration with Bacillus subtilis on immune cells in the nasal mucosa and tonsils of piglets. Exp Ther Med. 2018;15:5189–5198.
   PubMed Web of Science ®Google Scholar
• Mårtensson a, Abolhalaj M, Lindstedt M, et al., Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: a randomized controlled trial: nasal effects of a LAB microbiome in CRSsNP. Laryngoscope Investig Otolaryngol 2017; 2(6): 410–416.
   PubMed Web of Science ®Google Scholar
• Mukerji SS, Pynnonen MA, Kim HM, et al. Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial. Otolaryngol Head Neck Surg. 2009;140(2):202–208.
   PubMed Web of Science ®Google Scholar
• Kaplan, A. Canadian guidelines for chronic rhinosinusitis: clinical summary. Canadian Family Physician 2013; 59(12):1275–1281.
   Google Scholar
• Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis.Otolaryngology–Head and Neck Surgery 2015;152(2):S1–S39
   Google Scholar
• Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary: ICAR executive summary. Int Forum Allergy Rhinol. 2016;6(S1):S3–S21.
   PubMedGoogle Scholar
• Felice GD, Barletta B, Butteroni C, et al. Use of probiotic bacteria for prevention and therapy of allergic diseases: studies in mouse model of allergic sensitization. J Clin Gastroenterol. 2008;42:S130–S132
   PubMed Web of Science ®Google Scholar
• Özdemir Ö. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data: various effects of probiotics in allergy. Clin Exp Immunol. 2010;160(3):295–304
   PubMed Web of Science ®Google Scholar
• Ren J, Zhao Y, Huang S, et al. Immunomodulatory effect of Bifidobacterium breve on experimental allergic rhinitis in BALB/c mice. Experimental and Therapeutic Medicine 2018;16:3996–4004.
   Google Scholar
• Giovannini M, Agostoni C, Riva E, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007;62(2):215–220. .
   PubMed Web of Science ®Google Scholar
• Güvenç IA, Muluk NB, Mutlu FŞ, et al. Do Probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and metaanalysis. Am J Rhinol Allergy. 2016;30(5):e157–e175.
   PubMed Web of Science ®Google Scholar
• Zajac AE, Adams AS, Turner JH. Asystematic review and meta-analysis of probiotics for the treatment of allergic rhinitis: probiotics for the treatment of AR. Int Forum Allergy Rhinol. 2015;5(6):524–532.
   PubMed Web of Science ®Google Scholar
• Peng Y, Li a, Yu L, et al., The role of probiotics in prevention and treatment for patients with allergic rhinitis: a systematic review. Am J Rhinol Allergy. 29(4): 292–298. en. 2015. .
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
   PubMed Web of Science ®Google Scholar
• Gelardi M, De Luca C, Taliente S, et al. Adjuvant treatment with a symbiotic in patients with inflammatory non-allergic rhinitis. J Biol Regul Homeost Agents. 2017;31:201–206.
   PubMed Web of Science ®Google Scholar
• Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657–1665. en. .
   PubMed Web of Science ®Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngology–Head and Neck Surgery 2015; 152(1_suppl), S1-S43.
   Google Scholar
• Manolova V, Flace a, Jeandet P, et al. Biomarkers induced by the immunomodulatory bacterial extract OM-85: unique roles for Peyer’s patches and intestinal epithelial cells. J Clinical Cellular Immunol. 2017;08:494.
   Google Scholar
• Dang AT, Pasquali C, Ludigs K, et al. OM-85 is an immunomodulator of interferon-beta production and inflammasome activity. Sci Rep. 2017 7, 43844. ;7. .
   Web of Science ®Google Scholar
• Huber M, Mossmann H, Bessler WG. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res. 2005 ;10(5):209–217. .
   PubMed Web of Science ®Google Scholar
• Luan H, Zhang Q, Wang L, et al. OM85-BV Induced the Productions of IL-1 beta, IL-6, and TNF-alpha via TLR4-and TLR2-Mediated ERK1/2/NF-kappa B Pathway in RAW264.7 Cells. J Interferon Cytokine Res. 2014 ;34(7):526–536.
   PubMed Web of Science ®Google Scholar
• Liao J-Y, Zhang T. Influence of OM-85 BV on hBD-1 and immunoglobulin in children with asthma and recurrent respiratory tract infection. Zhongguo Dang Dai Er Ke Za Zhi. 201416(5):508–512..
   PubMedGoogle Scholar
• Roth M, Pasquali C, Stolz D, et al., Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP. Plos One 2017. 12(11): e0188010. 2017. .
   Google Scholar
• Strickland DH, Judd S, Thomas JA, et al. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol. 2011;4(1):43–52.
   PubMed Web of Science ®Google Scholar
• Fu R, Li J, Zhong H, et al. Broncho-Vaxom attenuates allergic airway inflammation by restoring GSK3β-related T regulatory cell insufficiency. PloS One 2014;9(3).
   Google Scholar
• Rodrigues a, Gualdi LP, De Souza RG, et al. Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model. Allergol Immunopathol (Madr). 2016 Nov-Dec;44(6):504–511.
   PubMed Web of Science ®Google Scholar
• Hua Zhong JW, Yao Y, Ran F, et al. a bacterial extract of OM-85 Broncho-Vaxom suppresses ovalbumin-induced airway inflammation and remodeling in a mouse chronic allergic asthma model. Int J Clin Exp Pathol. 2017;10:8.
   Web of Science ®Google Scholar
• Lu Y, Li Y, Xu L, et al. Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children. Pharmacology. 2015;95(3–4):139–144. .
   PubMed Web of Science ®Google Scholar
• Boer G, Żółkiewicz J, Strzelec K, et al. Bacterial lysate add-on therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis Eur Resp Rev 2020 [under revision].
   Google Scholar
• Chen ZGJ, Li JZ, Chen M, et al. Effect and analysis of clinical efficacy of immunomodulator on serum levels of IL-4 and IFN-gamma in asthmatic children. J Sun Yat-sen Univ Med Sci. 2009;30(3) ( Chinese).
   Google Scholar
• Han RF, Li HY, Wang JW, et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom. Eur Rev Med Pharmacol Sci. 2016 ;20(10):2151–2155. .
   PubMed Web of Science ®Google Scholar
• Yin J, Xu B, Zeng X, et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: a systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov: NCT02148796. [cited 2019 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02148796
   Google Scholar
• Emmerich B, Pachmann K, Milatovic D, et al. Influence of OM-85 BV on different humoral and cellular immune defense mechanisms of the respiratory tract. Respiration. 1992;59(3):19–23.
   PubMedGoogle Scholar
• Zou Y, Chen X, Liu J, et al. Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters. Int J Chron Obstruct Pulmon Dis20171247–1254.
   PubMedGoogle Scholar
• Pan L, Jiang X-G, Guo J, et al. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Clin Pharmacol. 2015 Oct;55(10):1086–1092. PubMed PMID: WOS:000360831700003.
   PubMed Web of Science ®Google Scholar
• Boer G, Braunstahl G. Bacterial lystes as add-on therapy in obstructive lung diseases: a systematic review and a meta-analysis. Abstract TP0797. European Academy of Allergy and Clinical Immunology (EAACI); 01-05 June; Lisbon, Portugal 2019.
   Google Scholar
• Bergemann R, Brandt A, Zoellner U, et al. Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis. Monaldi Arch Chest Dis. 1994 ;49(4):302–307. .
   PubMedGoogle Scholar
• Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Respir J. 2001;8(1):27–33.
   PubMedGoogle Scholar
• Koatz a, Zakin L, Ciceran a. Cost consequence of preventive treatment with OM-85 bacterial lysate compared to the same patients without OM-85 the previous year in allergic rhinitis, asthma and COPD in Argentina. Value Health. 2015;18(7):A498.
   Web of Science ®Google Scholar
• Tao Y, Yuan T, Li X, et al. Bacterial extract OM-85 BV protects mice against experimental chronic rhinosinusitis. Int J Clin Exp Pathol. 2015;8(6):6800–6806.
   PubMed Web of Science ®Google Scholar
• Triantafillou V, Workman AD, Patel NN, et al. Broncho‐Vaxom® (OM‐85 BV) soluble components stimulate sinonasal innate immunity. Int Forum Allergy Rhinol. 2019;9(4):370–377. en. .
   PubMed Web of Science ®Google Scholar
• Zagar S, Löfler-Badzek D. Broncho-vaxom® in children with rhinosinusitis: a double-blind clinical trial. ORL. 1988;50(6):397–404.
   Google Scholar
• Chen J, Zhou Y, Nie J, et al..Bacterial lysate for the prevention of chronic rhinosinusitis recurrence in children. J Laryngol Otol. 2017;131(6):523–528.
   PubMed Web of Science ®Google Scholar
• Heintz B, Schlenter W, Kirsten R, et al. Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis–a multi-centric, placebo-controlled, double-blind study. International journal of clinical pharmacology, therapy, and toxicology, 1989, 27(11): 530-534..
   Google Scholar
• Xuan J, Wang L, Yin H, et al. The cost-effectiveness of OM-85 in managing respiratory tract infections in China. J Med Econ. 2015 Mar;18(3):167–172.
   PubMed Web of Science ®Google Scholar
• Dibildox-Martinez J, Mayorga Butron JL, Macías Fernández LA, et al. Pan-American clinical guideline on rhinosinusitis. Otolaryngol Head Neck Surg. 2012;147(2_suppl):P253–P253
   Google Scholar
• Han L, Zheng C-P, Sun Y-Q, et al. Abacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014 Mar-Apr;28(2):110–116.
   PubMed Web of Science ®Google Scholar
• Koatz AM, Coe NA, Cicerán A, et al. Clinical and Immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. Lung. 2016;194(4):687–697.
   PubMed Web of Science ®Google Scholar
• Meng Q, Li P, Li Y, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology 2019; 57(6), 451-459.
   Google Scholar
• Cazzola M, Capuano A, Rogliani P, et al. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012;12(3):300–308. .
   PubMed Web of Science ®Google Scholar
• Esposito S, Garziano M, Rainone V, et al. Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. J Transl Med. 2015 ;3;13. PubMed
   PubMed Web of Science ®Google Scholar
• Carta S, Silvestri M, Rossi GA. Modulation of airway epithelial cell functions by Pidotimod: NF-kappa B cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Ital J Pediatr. 2013 10;39. .
   PubMed Web of Science ®Google Scholar
• Kim C-H, Kim D-J, Lee S-J, et al. Toll-like receptor 2 promotes bacterial clearance during the initial stage of pulmonary infection with Acinetobacter baumannii. Mol Med Rep. 2014;9(4):1410–1414.
   PubMed Web of Science ®Google Scholar
• Ferrario BE, Garuti S, Braido F, et al. Pidotimod: the state of art. Clinical and molecular allergy. CMA. 2015;13(1):8. P.
   Google Scholar
• Singh DP, Bagam P, Sahoo MK, et al. Immune-related gene polymorphisms in pulmonary diseases. Toxicology. 2017;383:24–39.
   PubMed Web of Science ®Google Scholar
• Gaballah HH, Gaber RA, Sharshar RS, et al. NOD2 expression, DNA damage and oxido-inflammatory status in atopic bronchial asthma: exploring their nexus to disease severity. Gene. 2018;660:128–135.
   PubMed Web of Science ®Google Scholar
• Gourgiotis D, Papadopoulos NG, Bossios a, et al. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma. 2004 ;41(3):285–287.
   PubMed Web of Science ®Google Scholar
• Polte T, Behrendt a, Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol. 2006;118(4):942–948.
   PubMed Web of Science ®Google Scholar
• Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. Faseb J. 1995;9(1):81–86.
   PubMed Web of Science ®Google Scholar
• Manetti R, Annunziato F, Biagiotti R, et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection.. J Exp Med. 1994;180(6):2407–2411.
   PubMed Web of Science ®Google Scholar
• Fu L-Q, Li Y-L, Fu a-K, et al. Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma. Mol Med Rep. 2017;16(4):4151–4158.
   PubMed Web of Science ®Google Scholar
• Namazova-Baranova LS, Alekseeva AA, Kharit SM, et al. Efficacy and safety of pidotimod in the prevention of recurrent respiratory infections in children: a multicentre study. Int J Immunopathol Pharmacol. 2014; 27(3):413–419.
   PubMed Web of Science ®Google Scholar
• Benetti G, Illeni M, Passera a, et al. Ex vivo evaluation of pidotimod activity in patients with chronic obstructive pulmonary disease. (0004-4172 (Print)). eng.
   Google Scholar
• Bisetti A, Ciappi G, Bariffi F, et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung, 1994; 44(12A), 1499-1502
   Google Scholar
• Pozzi E, Dolcetti A, Orlandi O, et al. Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchitis. 1994:1495–1498.
   Google Scholar
• CiacciaA .Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung 1994; 44(12A), 1516-1520
   Google Scholar
• Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012;25(1):62–68.
   PubMed Web of Science ®Google Scholar
• Bartkowiak-Emeryk M, et al. The influence of polyvalent mechanical bacterial lysate on immunological parameters in asthmatic children. Abstract 0078. European Academy of Allergy and Clinical Immunology Congress; 17-21 June 2017; Helsinki 2017.
   Google Scholar
• Lanzilli G, Traggiai E, Braido F, et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: effects on circulating T, B and NK cells. Immunol Lett. 2013 ;149(1–2):62–67.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Noschese P, Di Perna F. Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. Ther Adv Respir Dis. 2009 ;3(2):59–63.
   PubMedGoogle Scholar
• Braido F, Melioli G, Cazzola M, et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulm Pharmacol Ther. 2015;33:75–80.
   PubMed Web of Science ®Google Scholar
• Ricci R, Palmero C, Bazurro G, et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulm Pharmacol Ther. 2014 27(1):109–113. .
   PubMed Web of Science ®Google Scholar
• Banche G, Allizond V, Mandras N, et al. Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects. Int J Immunopathol Pharmacol. 2007;20(1):129–138. en.
   PubMed Web of Science ®Google Scholar
• Janeczek K, Emeryk A, Rapiejko P. Effect of polyvalent bacterial lysate on the clinical course of pollen allergic rhinitis in children. Adv Dermatol Allergology. 2019;36(4):504–505.
   PubMed Web of Science ®Google Scholar
• Mulder WJM, Ochando J, Joosten LAB, et al. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18(7):553–566. en. .
   PubMed Web of Science ®Google Scholar